Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...
Yesterday, the Pharma giant Pfizer Inc. (PFE) took the unusual step of not only providing its full-year 2025 revenue and earnings numbers but also providing precise guidance for full-year 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results